Application of Ex Vivo Non-Viral Gene Therapy and Facilitating Engraftment of Gene-Corrected Hematopoietic Stem Cells

Time: 11:15 am
day: Day Two


  • Delivery of Poseida’s platform technology in gene addition (piggyBac transposons) and gene-editing (Cas-Clover CRISPR)
  • Production of pure CAR-T and HSC products
  • HSC homing and expansion
  • Selective targeting of HSCs for safer transplant conditioning